Home > Boards > US OTC > Biotechs >

Talon Therapeutics, Inc. (TLON)

TLON RSS Feed
Add TLON Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/14/2020 10:26:16 AM - Followers: 95 - Board type: Free - Posts Today: 0

 

 



is since dec. 2010



 

Company Overview

Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States - http://maps.yahoo.com/maps_result?addr=2207%20Bridgepointe%20Parkway%20Suite%20250&csz=San%20Mateo%20CA%2094404&country=United%20States" rel="nofollow">Map
Phone:                650-588-6404       
Fax: 650-588-2787
Website: http://www.talontx.com
 

Business Summary  

Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of adult acute lymphoblastic leukemia. The company's product candidates also include Menadione Topical Lotion, a supportive care product candidate that completed Phase 1 clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of lung, colon, head and neck, pancreatic, and breast cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of metastatic carcinoma of the ovary and small cell lung cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California

   

Current Pipeline

 

 



Overview

Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »
 





Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »

Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »

Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details »


Presentations


Presentations
Talon Therapeutics Corporate Presentation   PDF 869.6 KB Add to Briefcase


Publications
VSLI (Vincristine Sulfate Liposomes Injection, Marqibo®) "Bridging" to Potentially Curative Hematopoietic Stem Cell Transplantation (HSCT) in Adults with Philadelphia Chromosome Negative (PH-) Acute Lymphoblastic Leukemia (ALL) 06/09/2011 PDF 151.1 KB Add to Briefcase
VSLI (vincristine sulfate liposomes injection) in the Treatment of Adult Subjects with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and rALLy Studies 12/05/2010 PDF 110.6 KB Add to Briefcase
Marqibo (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) 12/05/2010 PDF

and more:

http://ir.talontx.com/presentations.cfm




INFOS
 

  • OTC Market Tier

    Pink Quote/OTCBB
  • Primary SIC - Industry Classification

    2834 - Pharmaceutical preparations
  • State Of Incorporation

    DE
  • Jurisdiction Of Incorporation

    United States

      

     

Board of Directors

Steven R. Deitcher, M.D.
President & Chief Executive Officer


Nishan de Silva, M.D.
Principal, Warburg Pincus

Andrew K. Ferrer
Associate, Warburg Pincus

Howard P. Furst, M.D.
Partner, Deerfield Management

Jonathan S. Leff
Managing Director, Warburg Pincus

Paul V. Maier
Chief Financial Officer, Sequenom, Inc.

Leon E. Rosenberg, M.D. (Chairman)
Professor of Molecular Biology, Princeton University

Robert J. Spiegel, M.D.
Director

 

  • SEC Reporting Status

    SEC Reporting Company
  • CIK

    0001140028
  • Fiscal Year End

    12/31

Current Share Structure

Current as of 12/31/2010

A/S 350,000,000

O/S 21,242,772 (Mar 28, 2011)

FLOAT  16.48M

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209

 


 Recent news

 

Tuesday, August 9, 2011

Wednesday, July 20, 2011

Tuesday, July 19, 2011

Monday, July 18, 2011

Friday, July 1, 2011

Thursday, June 30, 2011

Friday, June 17, 2011

Monday, June 6, 2011

Thursday, May 19, 2011

Friday, May 13, 2011

Tuesday, May 10, 2011

Monday, May 9, 2011

Monday, March 28, 2011

Thursday, March 24, 2011

Monday, March 14, 2011

Thursday, March 10, 2011

Wednesday, January 12, 2011

   
   
   
   
   
   


Charting


 

 

New presentation from tlon from 3-30-12

http://files.shareholder.com/downloads/HNAB/1722627662x0x556820/A59F1E05-C4F6-4235-B039-7B3CCE775B48/talontx_corp_pres.pdf

TLON
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#6028   TLON CVRs are now with a new agent, Equiniti operating_line 09/14/20 10:26:16 AM
#6027   Did you ever find out why they took CVR Investor 08/25/20 09:17:05 AM
#6026   We all TLON investors can seek Helps from FLY HIGH NOW 06/24/20 06:09:20 PM
#6025   best chance is something from CASI first in China operating_line 06/18/20 12:11:35 AM
#6024   Previously I saw May 2021 for clinical trials operating_line 06/17/20 11:47:11 PM
#6023   Okay, I see what you mean. I still CVR Investor 06/17/20 05:31:01 PM
#6022   We need to see a milestone being met operating_line 06/12/20 11:44:40 PM
#6021   I think we should call the SEC. I CVR Investor 06/12/20 12:30:43 PM
#6020   @Operating_line - It's a long time waiting. CVR Investor 06/12/20 12:22:05 PM
#6019   Any brokers Can’t Remove the Stocks with Waiting FLY HIGH NOW 06/10/20 02:59:45 AM
#6018   yes, I give it a low chance of operating_line 06/05/20 11:55:18 AM
#6017   Really doesn't hurt me since I wrote off ErnieBilco 06/05/20 11:51:38 AM
#6016   Just because a broker gives that excuse, I operating_line 06/05/20 11:37:35 AM
#6015   Firsttrade just trashed the CVRs - 6 years ErnieBilco 06/05/20 11:07:52 AM
#6014   Any sales of Marqibo help to trigger the operating_line 06/05/20 10:52:37 AM
#6013   What does CASI have to do with the mc1005 06/05/20 10:44:23 AM
#6012   CASI: A Change in Strategy operating_line 06/04/20 11:46:56 PM
#6011   We all have waited so long for our FLY HIGH NOW 04/19/20 01:22:21 AM
#6010   I also want to receive my investment back. operating_line 03/25/20 10:15:42 PM
#6009   Does it mean we all Tlon investors will FLY HIGH NOW 03/25/20 01:23:56 PM
#6008   No sign of progress yet operating_line 03/25/20 05:10:45 AM
#6007   When Spectrums sold Marqibo ...to Acrotech for $160 FLY HIGH NOW 03/24/20 03:57:01 PM
#6006   Information on CVR milestones was posted here: operating_line 03/23/20 08:34:57 AM
#6005   Patience under uncertainty: also hoping for CVR distribution operating_line 03/23/20 08:32:43 AM
#6004   That is more than a year ago can xlofer 02/26/20 12:02:40 AM
#6003   I just talked to Askley 2/21/20 ( Spectrum FLY HIGH NOW 02/21/20 06:15:40 PM
#6002   Thief hopefully they get bankrupt. You start we xlofer 02/19/20 01:48:05 AM
#6001   We also call SEC to Complain about TLON FLY HIGH NOW 02/18/20 04:32:11 PM
#6000   That is a good and clear name for FLY HIGH NOW 02/18/20 04:28:02 PM
#5999   We should have a class action lawsuits together FLY HIGH NOW 11/14/19 09:52:16 AM
#5998   Yes we should fight for it. I'm still CVR Investor 10/28/19 11:00:25 AM
#5997   We haven’t received any money in our brokers FLY HIGH NOW 10/16/19 01:10:38 PM
#5996   The Spectrum CVR are now renamed to TALON upanddown66 10/16/19 10:50:09 AM
#5995   Still waiting, hopefully we will see something, talk xlofer 09/29/19 06:53:18 PM
#5994   We should have some money back for our FLY HIGH NOW 09/27/19 06:32:56 PM
#5993   R we ever gonna see anything out of SPPI xlofer 08/31/19 02:35:55 AM
#5992   we hope to get our money back soon....we FLY HIGH NOW 07/31/19 12:32:32 PM
#5991   I still hope one day we will get xlofer 07/24/19 12:07:12 AM
#5990   Anyone know any revenues about TLON? where are FLY HIGH NOW 07/22/19 12:12:01 AM
#5989   Anyone knows anything about our money from TLON? FLY HIGH NOW 07/06/19 02:26:20 PM
#5988   Do we ever gonna see our Money. xlofer 01/31/19 12:36:46 AM
#5987   Marqibo sold to Acrotech Biopharma, subsidiary of Aurobindo operating_line 01/23/19 02:20:50 AM
#5986   If you did not receive that cash and operating_line 12/05/18 12:47:53 AM
#5985   My guess is 2020 could be possible but operating_line 12/05/18 12:45:30 AM
#5984   Haven't been here for years. Any help me bmatt 11/29/18 02:08:20 PM
#5983   R we ever will see any Money. Anyone. xlofer 11/29/18 03:18:34 AM
#5982   Spectrum Pharmaceuticals Q3 2018: MARQIBO® net sales operating_line 11/18/18 09:32:04 AM
#5981   CASI Pharmaceuticals To Build GMP Manufacturing Site operating_line 11/17/18 06:21:04 AM
#5980   CASI funding and new CFO operating_line 09/29/18 12:44:41 AM
#5979   You have the CVR payment schedule information from operating_line 08/19/18 05:01:34 AM
PostSubject
Consent Preferences